ENANTA PHARMACEUTICALS INC Nonoperating Income (Expense) in USD from 2011 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Enanta Pharmaceuticals Inc quarterly/annual Nonoperating Income (Expense) history and growth rate from 2011 to Q3 2025.
  • Enanta Pharmaceuticals Inc Nonoperating Income (Expense) for the quarter ending September 30, 2025 was -$282K, a 142% decline year-over-year.
  • Enanta Pharmaceuticals Inc Nonoperating Income (Expense) for the twelve months ending September 30, 2025 was $1.8M, a 53.9% decline year-over-year.
  • Enanta Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2025 was $1.8M, a 53.9% decline from 2024.
  • Enanta Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2024 was $3.9M, a 37.2% decline from 2023.
  • Enanta Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2023 was $6.21M, a 275% increase from 2022.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)

ENANTA PHARMACEUTICALS INC Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $1.8M -$282K -$950K -142% Jul 1, 2025 Sep 30, 2025 10-K 2025-11-19
Q2 2025 $2.75M $667K -$465K -41.1% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-13
Q1 2025 $3.22M $578K -$668K -53.6% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-14
Q4 2024 $3.88M $837K -$20K -2.33% Oct 1, 2024 Dec 31, 2024 10-Q 2025-02-12
Q3 2024 $3.9M $668K -$845K -55.8% Jul 1, 2024 Sep 30, 2024 10-K 2025-11-19
Q2 2024 $4.75M $1.13M -$737K -39.4% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-13
Q1 2024 $5.49M $1.25M -$591K -32.2% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-14
Q4 2023 $6.08M $857K -$136K -13.7% Oct 1, 2023 Dec 31, 2023 10-Q 2025-02-12
Q3 2023 $6.21M $1.51M +$763K +102% Jul 1, 2023 Sep 30, 2023 10-K 2025-11-19
Q2 2023 $5.45M $1.87M +$1.48M +376% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $3.97M $1.84M +$1.58M +620% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $2.39M $993K +$735K +285% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-08
Q3 2022 $1.66M $750K +$417K +125% Jul 1, 2022 Sep 30, 2022 10-K 2024-11-27
Q2 2022 $1.24M $393K -$46K -10.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $1.29M $255K -$290K -53.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $1.58M $258K -$419K -61.9% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-08
Q3 2021 $1.99M $333K -$816K -71% Jul 1, 2021 Sep 30, 2021 10-K 2023-11-22
Q2 2021 $2.81M $439K -$1.01M -69.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $3.82M $545K -$1.41M -72.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $5.22M $677K -$1.4M -67.4% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-10
Q3 2020 $6.62M $1.15M -$1.13M -49.5% Jul 1, 2020 Sep 30, 2020 10-K 2020-11-25
Q2 2020 $7.75M $1.45M -$970K -40.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $8.72M $1.95M -$295K -13.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $9.01M $2.08M +$191K +10.1% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-09
Q3 2019 $8.82M $2.27M +$845K +59.1% Jul 1, 2019 Sep 30, 2019 10-K 2020-11-25
Q2 2019 $7.97M $2.42M +$1.08M +80.5% Apr 1, 2019 Jun 30, 2019 10-K 2020-11-25
Q1 2019 $6.9M $2.25M +$1.18M +111% Jan 1, 2019 Mar 31, 2019 10-K 2020-11-25
Q4 2018 $5.72M $1.89M +$925K +96.4% Oct 1, 2018 Dec 31, 2018 10-K 2020-11-25
Q3 2018 $4.79M $1.43M +$769K +117% Jul 1, 2018 Sep 30, 2018 10-K 2019-11-27
Q2 2018 $4.02M $1.34M +$738K +123% Apr 1, 2018 Jun 30, 2018 10-K 2019-11-27
Q1 2018 $3.29M $1.07M +$517K +94.2% Jan 1, 2018 Mar 31, 2018 10-K 2019-11-27
Q4 2017 $2.77M $960K +$436K +83.2% Oct 1, 2017 Dec 31, 2017 10-K 2019-11-27
Q3 2017 $2.33M $660K +$189K +40.1% Jul 1, 2017 Sep 30, 2017 10-K 2018-11-29
Q2 2017 $2.14M $600K +$153K +34.2% Apr 1, 2017 Jun 30, 2017 10-K 2018-11-29
Q1 2017 $1.99M $549K +$77K +16.3% Jan 1, 2017 Mar 31, 2017 10-K 2018-11-29
Q4 2016 $1.91M $524K +$195K +59.3% Oct 1, 2016 Dec 31, 2016 10-K 2018-11-29
Q3 2016 $1.72M $471K -$38K -7.47% Jul 1, 2016 Sep 30, 2016 10-K 2018-11-29
Q2 2016 $1.76M $447K +$160K +55.7% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $1.6M $472K +$262K +125% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 $1.34M $329K +$28K +9.3% Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-09
Q3 2015 $1.31M $509K +$273K +116% Jul 1, 2015 Sep 30, 2015 10-K 2017-12-11
Q2 2015 $1.03M $287K +$251K +697% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 $783K $210K +$286K Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 $497K $301K +$214K +246% Oct 1, 2014 Dec 31, 2014 10-Q 2016-02-09
Q3 2014 $283K $236K -$22K -8.53% Jul 1, 2014 Sep 30, 2014 10-K 2016-12-09
Q2 2014 $305K $36K -$4K -10% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-10
Q1 2014 $309K -$76K -$328K -130% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-08
Q4 2013 $637K $87K +$39K +81.3% Oct 1, 2013 Dec 31, 2013 10-Q 2015-02-06
Q3 2013 $598K $258K Jul 1, 2013 Sep 30, 2013 10-K 2015-12-11
Q2 2013 $40K +$13K +48.1% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-12
Q1 2013 $252K +$236K +1475% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-12
Q4 2012 $48K Oct 1, 2012 Dec 31, 2012 10-Q 2014-02-13
Q2 2012 $27K Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-12
Q1 2012 $16K Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-15

ENANTA PHARMACEUTICALS INC Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2025 $1.8M -$2.1M -53.9% Oct 1, 2024 Sep 30, 2025 10-K 2025-11-19
2024 $3.9M -$2.31M -37.2% Oct 1, 2023 Sep 30, 2024 10-K 2025-11-19
2023 $6.21M +$4.56M +275% Oct 1, 2022 Sep 30, 2023 10-K 2025-11-19
2022 $1.66M -$338K -17% Oct 1, 2021 Sep 30, 2022 10-K 2024-11-27
2021 $1.99M -$4.63M -69.9% Oct 1, 2020 Sep 30, 2021 10-K 2023-11-22
2020 $6.62M -$2.2M -24.9% Oct 1, 2019 Sep 30, 2020 10-K 2022-11-23
2019 $8.82M +$4.03M +84% Oct 1, 2018 Sep 30, 2019 10-K 2021-11-24
2018 $4.79M +$2.46M +105% Oct 1, 2017 Sep 30, 2018 10-K 2020-11-25
2017 $2.33M +$614K +35.7% Oct 1, 2016 Sep 30, 2017 10-K 2019-11-27
2016 $1.72M +$412K +31.5% Oct 1, 2015 Sep 30, 2016 10-K 2018-11-29
2015 $1.31M +$1.02M +362% Oct 1, 2014 Sep 30, 2015 10-K 2017-12-11
2014 $283K -$315K -52.7% Oct 1, 2013 Sep 30, 2014 10-K 2016-12-09
2013 $598K +$488K +444% Oct 1, 2012 Sep 30, 2013 10-K 2015-12-11
2012 $110K +$2.1M Oct 1, 2011 Sep 30, 2012 10-K 2014-12-11
2011 -$1.99M Oct 1, 2010 Sep 30, 2011 10-K 2013-12-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.